title: First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver Transplantation.
abstract: Mesenchymal stem cells and multipotent adult progenitor cells (MAPCs) have been proposed as novel therapeutics for solid organ transplant recipients with the aim of reducing exposure to pharmacological immunosuppression and its side effects. In the present study, we describe the clinical course of the first patient of the phase I, dose-escalation safety and feasibility study, MiSOT-I (Mesenchymal Stem Cells in Solid Organ Transplantation Phase I). After receiving a living-related liver graft, the patient was given one intraportal injection and one intravenous infusion of third-party MAPC in a low-dose pharmacological immunosuppressive background. Cell administration was found to be technically feasible; importantly, we found no evidence of acute toxicity associated with MAPC infusions.
authors.affiliation: Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA.
authors.forename: Yorick
authors.initials: Y
authors.lastname: Soeder
authors.affiliation: Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA.
authors.forename: Martin
authors.initials: M
authors.lastname: Loss
authors.affiliation: Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA.
authors.forename: Christian L
authors.initials: CL
authors.lastname: Johnson
authors.affiliation: Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA.
authors.forename: James A
authors.initials: JA
authors.lastname: Hutchinson
authors.affiliation: Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA.
authors.forename: Jan
authors.initials: J
authors.lastname: Haarer
authors.affiliation: Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA.
authors.forename: Norbert
authors.initials: N
authors.lastname: Ahrens
authors.affiliation: Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Offner
authors.affiliation: Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Deans
authors.affiliation: Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA.
authors.forename: Gil
authors.initials: G
authors.lastname: Van Bokkelen
authors.affiliation: Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA.
authors.forename: Edward K
authors.initials: EK
authors.lastname: Geissler
authors.affiliation: Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA.
authors.forename: Hans J
authors.initials: HJ
authors.lastname: Schlitt
authors.affiliation: Department of Surgery and Institute for Clinical Chemistry, Laboratory Medicine, and Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany; Athersys Inc., Cleveland, Ohio, USA marc.dahlke@ukr.de.
authors.forename: Marc H
authors.initials: MH
authors.lastname: Dahlke
mesh_terms: D000328:Adult; D053687:Adult Stem Cells / Q000637:transplantation*; D006084:Graft Rejection; D006801:Humans; D056747:Immunomodulation; D007165:Immunosuppression Therapy; D008103:Liver Cirrhosis / Q000473:pathology / Q000628:therapy*; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology; D039902:Multipotent Stem Cells / Q000637:transplantation
keywords: Cell therapy; Immunomodulation; Liver transplantation; Mesenchymal stem cells; Multipotent stem cells; Tolerance